King-Friend subsidiary advances Xentria collaboration

Nanjing King-Friend Biochemical Pharmaceutical (SSE:603707) announced that its subsidiary, Hong Kong King-Friend Industrial, made a $5 million milestone payment to Xentria on March 5, 2025, in accordance with their licensing agreement. This payment follows the completion of subject screening for the Phase 2 clinical trial. XTMAB, a TNFα inhibitor targeting immune dysregulation, previously received FDA orphan drug designation in November 2020. To date, King-Friend subsidiaries have cumulatively paid Xentria $10 million related to the XTMAB project. The company cautions that the project remains in Phase 2 clinical trials, and potential returns are subject to regulatory approvals and market conditions.